2022ÄêÅ·ÖÞÖ×ÁöÄÚ¿ÆÑ§»á(ESMO)Äê»áÓÚ9ÔÂ9ÈÕÖÁ13ÈÕÔÚ·¨¹ú°ÍÀèÒÔ¡°ÏßÉÏ+ÏßÏ¡±ÐÎʽ¾ÙÐС£µÏÍþÖÆµÏÍþ¹ú¼Ê×ÔÖ÷´´ÐµÏÍþ¹ú¼Ê¼×»ÇËá°¢ÃÀÌæÄáÆ¬(ÉÌÆ·Ãû£º°¢ÃÀÀÖ?)Á½ÆªÏà¹ØÑо¿ÕªÒªÈëÑ¡£¬·Ö±ðÔÚÔçÆÚºÍÍíÆÚ·Î°©ÁìÓò´øÀ´×îпÆÑ§½øÕ¹¡£
×÷ΪŷÖÞ×ʢÃûºÍ×î¾ßÓ°ÏìÁ¦µÄÖ×Áöѧ»áÒ飬ÿ½ìESMOÄê»á¶¼Óг¬¹ý30,000ÃûרҵÈËÊ¿²Î¼Ó£¬ÒѾ³ÉΪÖ×ÁöÁìÓòÁÙ´²×¨¼ÒºÍÒ½µÏÍþ¹ú¼ÊÆóÒµ¸ú×ÙÈ«Çò×îÐÂÁÙ´²Ñо¿½øÕ¹¡¢ÁÙ´²Êµ¼ù¼°Ò½ÁƼ¼ÊõÐÅÏ¢µÄ·çÏò±ê¡£
°¢ÃÀÌæÄáÊǵÏÍþÖÆµÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄÊ׸öÖйúÔ´´Èý´úEGFR-TKI£¬Ò²ÊÇÈ«ÇòÊ׸öÖÐλÎÞ½øÕ¹Éú´æÆÚ(mPFS)³¬¹ý1Äê(¶þÏßʹÓÃ)µÄÈý´úEGFR-TKI£¬Æ¾½è׿ԽµÄÁÆÐ§ºÍ°²È«ÐÔÓÅÊÆ£¬ÂŴλñµÃ¹ú¼ÊȨÍþÈϿɡ£½üÆÚ£¬°¢ÃÀÌæÄáAENEASÑо¿½á¹ûÔÚ¹ú¼ÊÖøÃûÖ×ÁöѧÆÚ¿¯¡¶ÁÙ´²Ö×ÁöѧÔÓÖ¾¡·(Journal of Clinical Oncology£¬JCO£¬IF:44.544)·¢±í£¬×îÐÂÄÔ×ªÒÆÑÇ×éÊý¾ÝÁÁÏàÃÀ¹úÁÙ´²Ö×Áöѧ»á(ASCO)Äê»á£¬21ƪժҪÔÚ2022Äê¹ú¼Ê·Î°©Ñо¿Ð»á(IASLC)ÊÀ½ç·Î°©´ó»á(WCLC)·¢±í¡£
±¾½ìESMOÄê»áÉÏ£¬Á½Æª°¢ÃÀÌæÄáÏà¹ØÑо¿ÕªÒªÈëÑ¡£¬´øÀ´°¢ÃÀÌæÄáÓë°ÂÏ£ÌæÄáÔÚEGFRÍ»±äNSCLCÖÐÁÆÐ§µÄ¼ä½Ó±È½Ï£¬ÒÔ¼°¸¨ÖúÖÎÁÆNSCLCµÄAPPOINTÑо¿µÄ×îнøÕ¹¡£
ÕªÒª±àºÅ£º1005P
Indirect treatment comparisons of relative efficacy for aumolertinib VS osimertinib in EGFR-positive non-small cell lung cancer (NSCLC)
°¢ÃÀÌæÄáÓë°ÂÏ£ÌæÄáÔÚEGFRÍ»±äNSCLCÖÐÁÆÐ§µÄ¼ä½Ó±È½Ï
×÷ÕߣºSanjay Popat, The Royal Marsden Hospital
¼ò½é£ºÕâÊÇÒ»Ïî°¢ÃÀÌæÄáÓë°ÂÏ£ÌæÄá¼äPFS¡¢OS¼°ÖÎÁÆÆÚ¼ä³öÏÖÈκγ̶Ȳ»Á¼Ê¼þ(AG-TEAE)µÄ궨¼ä½ÓÖÎÁƱȽϣ¨indirect treatment comparison, ITC£©£¬Ê¹ÓÃÁËÁ½ÖÖ·ÖÎö·½·¨£¬Ò»ÖÖΪ»ùÓÚAENEASÑо¿£¨°¢ÃÀÌæÄᣩºÍFLAURAÑо¿£¨°ÂÏ£ÌæÄᣩÒÑ·¢±í»ã×ÜÊý¾ÝµÄBucher·¨ITC£¬ÁíÒ»ÖÖΪ»ùÓÚAENEASÑо¿»¼ÕßˮƽÊý¾ÝºÍFLAURAÑо¿ÒÑ·¢±í»ã×ÜÊý¾ÝµÄÄ£ÄâÖÎÁƱȽϣ¨simulated treatment comparison, STC£©¡£STCÖиù¾ÝAENEASÑо¿ÖÐÈËÈºÌØÕ÷ºÍ½á¹ûÖ®¼äµÄ¹ØÏµ£¬¶ÔAENEASÑо¿ÖеϼÕß½øÐÐÁ˻عéµ÷Õû£¬ÒÔÔ¤²âFLAURAÑо¿ÈËȺÖеÄÔ¤ÆÚ½á¹û£¬»Ø¹éÄ£Ð͸ù¾ÝÈ·¶¨µÄDZÔÚЧӦÐÞÊÎÒòËØºÍÑо¿Öв»Æ½ºâµÄÔ¤ºóÒòËØ½øÐÐÁ˵÷Õû¡£¶ÔÓÚÖ÷ÒªÑо¿ÖÕµãPFS£¬°¢ÃÀÌæÄá¶Ô±È°ÂÏ£ÌæÄáµÄBucher HRΪ1.00£¨95% CI:0.72-1.39£©£¬STC HRΪ0.98£¨95% CI:0.68-1.42£©£¬¾ùÌáʾÎÞͳ¼ÆÑ§²îÒì¡£¶ÔÓÚOS£¬Bucher HRÎÞͳ¼ÆÑ§²îÒ죨1.02¡¾95% CI: 0.67-1.56¡¿£©£¬µ«STC HRÔòÌáʾÓÐÀûÓÚ°¢ÃÀÌæÄáµÄOSÊýÖµ²îÒ죨0.73¡¾95% CI: 0.44-1.22¡¿£©¡£·ÖÎöʱ£¬AENEASÑо¿µÄOSÊý¾ÝÉÐδ³ÉÊì¡£¶ÔÓÚAG-TEAE£¬Bucher ORΪ0.65£¨95% CI:0.08-5.50£©¡£
ÕªÒª±àºÅ£º948TiP
Efficacy and safety of almonertinib in the adjuvant treatment of resectable stage I non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-sensitizing mutations in solid and/or micropapillary components
°¢ÃÀÌæÄḨÖúÖÎÁÆ¿ÉÇгýµÄ¢ñÆÚº¬ÊµÌåºÍ£¯»ò΢ÈéÍ·³É·ÖEGFRÃô¸ÐÍ»±äµÄ·ÇСϸ°û·Î°©µÄÁÆÐ§ºÍ°²È«ÐÔ(APPOINTÑо¿)
×÷Õߣºº«±¦»Ý ÉϺ£ÊÐÐØ¿ÆÒ½Ôº
¼ò½é£º²¡ÀíÑÇÐÍÊǶÀÁ¢ÓÚTNM·ÖÆÚµÄÔ¤ºóÖ¸±ê£¬ÆäÖÐЯ´øÎ¢ÈéÍ·¼°ÊµÌå³É·ÖµÄ»¼ÕßÔ¤ºó½Ï²î¡£¼ÈÍùÑо¿·¢ÏÖ£¬Î¢ÈéÍ·³É·ÖµÄ´æÔÚÓëIÆÚ·ÎÏÙ°©»¼Õ߸ü²îµÄÎÞ¸´·¢Éú´æÆÚ£¨RFS£©ÏÔÖøÏà¹Ø£¬¼´Ê¹ÊÇIAÆÚ»¼Õߣ¬Êõºó¸¨Öú»¯ÁÆÈÔ¿É´øÀ´»ñÒæ¡£Èý´úEGFR-TKIÒÑÔÚEGFRÍ»±äNSCLC »¼ÕßÖÐÏÔʾ³öÊõºó¸¨ÖúÖÎÁƵÄDZÁ¦£¬µ«ÉÐÎÞÓÃÓÚ¾ßÓиßΣ¸´·¢ÒòËØ£¨ÈçʵÌåºÍ΢ÈéÍ·³É·Ö£©µÄIÆÚNSCLC»¼ÕßµÄϵͳÑо¿¡£APPOINTÑо¿ÊÇÒ»ÏîÕýÔÚ½øÐÐÖеĶàÖÐÐÄÑо¿£¬½«Ê×´Î̽ÌÖ°¢ÃÀÌæÄáÔÚEGFRÃô¸ÐÍ»±äIÆÚº¬ÊµÌåºÍ/»ò΢ÈéÍ·³É·Ö¡Ý10£¥µÄNSCLC¸ùÖÎÐÔÊõºó»¼ÕßÖУ¬Êõºó¸¨ÖúÖÎÁƵÄÁÆÐ§ºÍ°²È«ÐÔ¡£Ñо¿ÄâÕÐļ104Àý»¼Õߣ¬ÆäÖÐ52Àý½«½ÓÊܰ¢ÃÀÌæÄá110mg qd×÷Ϊ¸¨ÖúÖÎÁÆ£¨¸¨ÖúÖÎÁƼƻ®Ê±¼äΪ3Ä꣩£¬52Àý½«½ÓÊÜÃÜÇÐËæ·Ã¹Û²ì¡£Ö÷ÒªÑо¿ÖÕµãÊÇ2ÄêDFSÂÊ£¬´ÎÒªÑо¿ÖÕµã°üÀ¨3¡¢4¡¢5ÄêµÄDFSÂÊ£¬5ÄêµÄ×ÜÉú´æÂÊ£¬°²È«ÐÔºÍÉú»îÖÊÁ¿¡£Ñо¿ÆÚ¼ä»¹½«¼à²âÑ»·Ö×ÁöDNA¡£Ä¿Ç°ÒÑÈë×é9Àý»¼Õß¡£